HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Isabelle Ray-Coquard Selected Research

Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)

12/2021Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
11/2021Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
2/2021Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
11/2020First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
7/2020Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
1/2017Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
1/2017Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Isabelle Ray-Coquard Research Topics

Disease

122Neoplasms (Cancer)
04/2022 - 06/2002
71Ovarian Neoplasms (Ovarian Cancer)
02/2022 - 03/2003
57Sarcoma (Soft Tissue Sarcoma)
01/2022 - 01/2004
30Breast Neoplasms (Breast Cancer)
01/2022 - 10/2002
25Carcinoma (Carcinomatosis)
02/2022 - 07/2006
16Fatigue
01/2022 - 07/2009
16Disease Progression
01/2022 - 05/2008
16Neutropenia
01/2022 - 05/2006
13Leiomyosarcoma
01/2022 - 08/2006
13Hypertension (High Blood Pressure)
01/2021 - 07/2009
12Anemia
01/2022 - 04/2003
12Neoplasm Metastasis (Metastasis)
01/2022 - 08/2005
12Ovarian Epithelial Carcinoma
11/2021 - 07/2014
12Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2020 - 08/2005
10Thrombocytopenia (Thrombopenia)
01/2022 - 10/2008
9Nausea
01/2022 - 07/2009
9Lymphopenia (Lymphocytopenia)
01/2022 - 12/2004
7Endometrial Neoplasms (Endometrial Cancer)
01/2022 - 12/2013
6Hemangiosarcoma (Angiosarcoma)
01/2022 - 11/2008
6Asthenia
01/2021 - 12/2016
6Vomiting
11/2020 - 12/2012
6Osteosarcoma (Osteogenic Sarcoma)
01/2020 - 08/2012
5Febrile Neutropenia
01/2022 - 12/2004
5Proteinuria
11/2020 - 07/2009
5Ewing Sarcoma (Sarcoma, Ewing)
01/2020 - 10/2008
5Stomatitis
01/2019 - 08/2012
5Renal Insufficiency (Renal Failure)
01/2016 - 01/2009
4Diarrhea
01/2022 - 08/2012
4Liposarcoma
12/2016 - 01/2004
4Synovial Sarcoma (Synovioma)
12/2016 - 01/2004
4Carcinogenesis
01/2015 - 05/2004
3Hemorrhage
01/2022 - 07/2014
3Fallopian Tube Neoplasms
12/2021 - 02/2014
3Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
10/2021 - 01/2021
3Colorectal Neoplasms (Colorectal Cancer)
04/2021 - 07/2007
3Pathologic Complete Response
01/2021 - 08/2011

Drug/Important Bio-Agent (IBA)

50PlatinumIBA
01/2022 - 03/2003
23Paclitaxel (Taxol)FDA LinkGeneric
02/2022 - 03/2003
21Bevacizumab (Avastin)FDA Link
01/2022 - 07/2007
21Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2021 - 01/2017
17TrabectedinIBA
01/2022 - 10/2008
17Imatinib Mesylate (Gleevec)FDA Link
01/2019 - 06/2002
16Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 08/2006
13Pharmaceutical PreparationsIBA
02/2021 - 01/2009
12olaparibIBA
01/2022 - 12/2016
12Biomarkers (Surrogate Marker)IBA
02/2021 - 05/2011
11Carboplatin (JM8)FDA LinkGeneric
02/2022 - 02/2004
10Hormones (Hormone)IBA
01/2022 - 07/2011
10liposomal doxorubicin (Doxil)FDA Link
11/2021 - 10/2010
9rucaparibIBA
12/2021 - 01/2017
9Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 07/2007
9pazopanibFDA Link
01/2020 - 07/2009
8IfosfamideFDA LinkGeneric
10/2020 - 08/2006
7Immune Checkpoint InhibitorsIBA
04/2022 - 01/2019
7Tyrosine Kinase InhibitorsIBA
01/2022 - 03/2007
7Biological ProductsIBA
01/2022 - 07/2007
7Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2021 - 01/2017
7Proteins (Proteins, Gene)FDA Link
04/2021 - 04/2008
7taxaneIBA
01/2021 - 07/2004
6Cisplatin (Platino)FDA LinkGeneric
10/2021 - 02/2004
6HematinicsIBA
02/2012 - 03/2008
5Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 03/2015
5cabozantinibIBA
01/2022 - 10/2014
5IronIBA
01/2022 - 03/2008
5AnthracyclinesIBA
07/2021 - 03/2003
5CreatinineIBA
01/2021 - 01/2009
5Hemoglobins (Hemoglobin)IBA
01/2021 - 08/2005
5Sunitinib (Sutent)FDA Link
01/2016 - 03/2007
5Docetaxel (Taxotere)FDA Link
01/2015 - 02/2004
5Sorafenib (BAY 43-9006)FDA Link
11/2014 - 01/2012
4Epoetin Alfa (Epogen)FDA Link
01/2022 - 03/2008
4regorafenibIBA
01/2022 - 01/2015
41-dodecylpyridoxal (PLD)IBA
11/2021 - 10/2010
4Alanine Transaminase (SGPT)IBA
01/2021 - 10/2008
4GemcitabineFDA Link
01/2021 - 08/2006
4AntigensIBA
04/2020 - 03/2009
4Phosphotransferases (Kinase)IBA
01/2020 - 03/2007
4ErbB Receptors (EGF Receptor)IBA
06/2016 - 08/2012
4EnzymesIBA
10/2010 - 05/2004
3nintedanibIBA
02/2022 - 01/2016
3lenvatinibIBA
01/2022 - 01/2021
3pembrolizumabIBA
01/2022 - 01/2021
3Aromatase InhibitorsIBA
01/2022 - 08/2012
3Poly Adenosine Diphosphate RiboseIBA
12/2021 - 01/2017
3Etoposide (VP 16)FDA LinkGeneric
10/2021 - 01/2020
3Messenger RNA (mRNA)IBA
04/2021 - 08/2011
3EverolimusFDA Link
01/2021 - 08/2012
3Angiogenesis InhibitorsIBA
01/2021 - 07/2007
3DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2007

Therapy/Procedure

84Drug Therapy (Chemotherapy)
02/2022 - 01/2003
83Therapeutics
02/2022 - 10/2002
8Radiotherapy
01/2022 - 09/2005
6Adjuvant Chemotherapy
01/2022 - 07/2004
6Neoadjuvant Therapy
10/2020 - 05/2004
5Immunotherapy
01/2022 - 01/2019
5Combination Drug Therapy (Combination Chemotherapy)
01/2019 - 02/2004
4Drug Tapering
01/2019 - 05/2006
3Contraception (Birth Control)
01/2022 - 03/2018
3Precision Medicine
01/2022 - 02/2021
3Aftercare (After-Treatment)
10/2021 - 02/2008